HOME >> BIOLOGY >> NEWS
Targeting tumor growth

Blood vessels nourish healthy tissues, but also provide a conduit for tumor growth and metastasis. A collaboration of researchers from the University of Michigan, NIH, and the University of Helsinki (Finland) has identified a novel, potential therapeutic target to prevent tumor vascularization.

In the April 15th cover story of Genes & Development, Dr. Stephen J. Weiss and colleagues demonstrate that "the recently characterized enzyme, termed the membrane-type 1 matrix metalloproteinase or MT1-MMP, controls the ability of new blood vessels to respond to a specific growth factor that plays a required role in maintaining the functional properties of the vasculature."

Mammalian vasculature is composed of two main cell types: endothelial cells (that line the blood vessels) and mural cells (that surround the endothelial tubules). Mural cells surrounding large vessels are known as vascular smooth muscle cells, while those on the surface of smaller vessels are called pericytes.

The platelet-derived growth factor- (PDGF-) intracellular signaling pathway has an established role in mediating cellular communication between endothelial and mural cells, which is essential for the normal formation of blood vessels. Dr. Weiss and colleagues have discovered that MT1-MMP, whose traditional role in endothelial and mural cells is to break down the proteins that reside in the spaces between cells, has an additional role in the regulation of PDGF- signaling.

To determine the effect of MT1-MMP on mural cell function, Dr. Weiss and colleagues used agenetically engineered a strain of mice that lacks MT1-MMP. Experimentation with these mice, and the MT1-MMP-null tissues derived from them, revealed that MT1-MMP helps propagate the PDGF- signal to direct mural cell investment in the microvasculature. MT1-MMP-null mice have severely compromised vascular architecture, with irregularly sized vessels and weakened vessel walls.

Dr. Weiss explains that "These
'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
31-Mar-2005


Page: 1 2

Related biology news :

1. Targeting key proteins of carcinogenesis
2. Targeting tumors the natural way
3. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
4. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
5. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
6. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
7. Targeting lung cancer
8. Targeting the dosage compensation complex
9. Targeting pancreatic cancer
10. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
11. Invasion of the brain tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, the world leader in ... in the award-winning study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee ... processed samples using Next Generation DNA Sequencing to examine the ability of NGS ...
(Date:11/6/2019)... Va. (PRWEB) , ... November 06, 2019 , ... ... today that Donald Stanski, MD, a senior pharmaceutical industry executive with expertise in ... and simulation for drug and disease strategic data analytics, has joined the firm ...
(Date:11/5/2019)... WA (PRWEB) , ... November 05, 2019 , ... ... & Amato Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including ... her Doctor of Dental Surgery degree from the University of Washington, Dr. Kopp ...
Breaking Biology News(10 mins):
(Date:11/27/2019)... ... November 25, 2019 , ... Silony Medical, a medical ... and navigated surgery in the UK. The procedure was performed in the UK’s ... Syed Aftab and Dr. Alexander Montgomery. The surgery, which took place on July ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and ... microturbine electrical power generation units from 2019-2028. The value of this production is ... of 3,821 units worth $569 million. , Reference to 2017 is important, ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... R&D, today announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical company ... to streamline their R&D operations related to the discovery and development of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... of the epidemic, which kills at least 30,000 people in the U.S. each ...
Breaking Biology Technology:
Cached News: